Deni Carise, PhD, the chief clinical officer for the Recovery Centers of America and adjunct clinical assistant professor at the University of Pennsylvania, said she applauds Brown’s comments.
Carise said since sufentanil has been approved in an injectable form for more than 20 years, the introduction of a new form that makes it easier to get into the hands of those who may use it illicitly “is dangerous.”
If the FDA doesn’t approve it for sale in the United States, Carise says the message is clear.
“This country doesn’t need another, more easily abused form of the potent opioid fentanyl to be approved,” she told Healthline. “The FDA has consistently shown an inability to safeguard our citizens from deadly prescription drugs. They are not equipped to do post-marketing analysis of prescribing behavior, and there has been evidence that there will be little in the way of education on appropriate prescribing practices.”
Read the full story HERE.
